Toronto, Ontario–(Newsfile Corp. – March 17, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the company has submitted a provisional patent application with the United States Patent and Trademark office, to cover the Company’s unique extraction processes for its proprietary Amanita muscaria extract AME-1.
The application was submitted on March 12, 2021 as App. No. 63/160,721, and discloses and claims muscimol extraction from Amanita mushrooms, and more particularly, enhanced muscimol extraction processes from Amanita muscaria, including by distillation and refluxing and/or pressing, resulting in a liquid or powder extract useful for preparations for human health.
“We have invested a lot of resources to develop AME-1 using a unique extraction protocol that we have developed,” said David Shisel COO of Psyched Wellness. “We believe that AME-1 has great potential and will be the foundation for many future products.”
Jeff Stevens, CEO of Psyched Wellness said, “Filing this provisional patent is key milestone for PSYC and our shareholders. We recognize the patent frenzy that is taking place in the sector and although we are the only company (we are aware of) studying Amanita Muscaria and, specifically, Muscimol, it is critical to protect our work and our shareholders from others infringing on our intellectual property. I see this as the first of many provisional patents to come.”
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.